Author

R. J. Summers

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Research Focus:development & morphogenesis· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Christopoulos· 1 shared A. Thapa· 1 shared B. Uricoli· 1 shared C. J. Langmead· 1 shared D. DeRyckere· 1 shared D. K. Graham· 1 shared E. C. Dreaden· 1 shared E. Costanza· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Christopoulos

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Constitutively synergistic multiagent drug formulations targeting MERTK, FLT3, and BCL-2 for treatment of AML

J. M. Kelvin, J. Jain, A. Thapa, M. Qui, L. A. Birnbaum, S. G. Moore, H. Zecca, R. J. Summers, E. Costanza, B. Uricoli, X. Wang, N. T. Jui, H. Fu, Y. Du, D. DeRyckere, , E. C. Dreaden

The paper develops a nanoscale combination drug formulation targeting MERTK, FLT3, and BCL-2 to treat AML, showing improved synergistic responses in vitro and in patient samples.

bioRxiv · Mar 13, 2023 · PreprintBioengineering

Pharmacological insights into safety and efficacy determinants for the development of adenosine receptor biased agonists in the treatment of heart failure

P. Rueda, J. Merlin, S. Chimenti, M. Feletou, J. Paysant, P. J. White, A. Christopoulos, P. M. Sexton, R. J. Summers, W. N. Charman, L. T. May, C. J. Langmead

This study compares the safety and efficacy of A1R agonists, showing that biased agonism away from Ca2+ influx relative to cAMP improves safety but may not guarantee efficacy in heart failure.

bioRxiv · Jul 22, 2020Pharmacology & Toxicology